Knottnerus SJG, et al
Thankfully just last year the first dengue fever vaccine got the green light in 3 countries: Mexico, the Philippines and Brazil
6 CT-868, an investigational, once-daily, subcutaneously injected dual GLP-1/GIP receptor agonist currently in Phase II with the potential to be a first in class treatment for glycaemic control as an adjunct to insulin in patients living with type 1 diabetes
Marek TRT protocols are commonly cited starting in the low $200s per month before labs and medication, so the real annual cost runs higher once monitoring is included
Critics and access advocates, including organisations like I-MAK, argue that this strategy is designed to create a legal moat so wide and deep that any generic competitor must spend decades and billions challenging individual patents in court, making market entry financially prohibitive
The significance of maintaining weight loss post-GLP-1 extends beyond the initial health benefits